Larimar Therapeutics (LRMR) Return on Equity [ROE] (2014 - 2026)
Larimar Therapeutics' Return on Equity [ROE] came in at -170.99% for Q2 2026, down 88.80 percentage points from -82.19% a year earlier.
Larimar Therapeutics (LRMR) Return on Equity [ROE] (2014 - 2026) Analysis & Trends
For FY2025, Larimar Therapeutics' Return on Equity [ROE] was -138.05%, down 66.36 percentage points from FY2024.
- Return on Equity [ROE] has declined in each of the last three years, with a five-year change of -41.86 percentage points (FY2020 to FY2025).
- Going back by year, Return on Equity [ROE] was -71.70% in FY2024 (-28.34 pp), -43.36% in FY2023 (-1.69 pp), -41.67% in FY2022 (+23.83 pp) and -65.49% in FY2021 (+30.70 pp).
- The Q2 2026 figure represents the lowest quarterly Return on Equity [ROE] since Q1 2020.
- Year-over-year, Return on Equity [ROE] increased in 1 of the last seven quarters, with an average year-over-year change of -50.69 percentage points.
- The fastest year-over-year change in Return on Equity [ROE] over five years came in Q2 2023 (a gain of 45.86 percentage points), and the weakest in Q4 2025 (a drop of 109.79 percentage points).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 74.39% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 19.33% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | - |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 5.63% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 21.60% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 72.13% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | -31.17% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 4.66% |
| 10 | Larimar Therapeutics | 279.45 Mn | -389.49 Mn | - | -120.95% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -120.95% |
| Mar 31, 2026 | -140.65% |
| Dec 31, 2025 | -152.69% |
| Sep 30, 2025 | -102.20% |
| Jun 30, 2025 | -75.45% |
| Mar 31, 2025 | -60.21% |
| Dec 31, 2024 | -43.51% |
| Sep 30, 2024 | -31.44% |
| Jun 30, 2024 | -26.46% |
| Mar 31, 2024 | -28.86% |
| Dec 31, 2023 | -42.24% |
| Sep 30, 2023 | -34.61% |
| Jun 30, 2023 | -31.59% |
| Mar 31, 2023 | -30.34% |
| Dec 31, 2022 | -30.83% |
| Sep 30, 2022 | -41.61% |
| Jun 30, 2022 | -81.39% |
| Mar 31, 2022 | -78.16% |
| Dec 31, 2021 | -74.20% |
| Sep 30, 2021 | -79.81% |
Larimar Therapeutics Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=LRMR&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "LRMR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=LRMR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();